Food Engineering / Gıda Mühendisliği

Permanent URI for this collectionhttps://hdl.handle.net/11147/12

Browse

Filters

2016 - 20192

Settings

Author: search.filters.author.Diego, Emilia

Search Results

Now showing 1 - 2 of 2
  • Conference Object
    Can Post-Mastectomy Radiation Therapy Be Omitted in T1-2 Clinically Node-Negative Breast Cancer Patients With a Positive Sentinel Lymph Node Biopsy?
    (Springer, 2019) Dinh, Kate; Soran, Atilla; Işık, Arda; McAuliffe, Priscilla; Diego, Emilia; Sezgin, Efe; Johnson, Ronald
    Background/Objective: The AMAROS trial demonstrated that both axillary radiation and axillary lymph node dissection (ALND) provide excellent locoregional control in patients with clinically node-negative T1-2 breast cancers and a positive sentinel lymph node biopsy (+SLNB). In that study, 18% of patients underwent total mastectomy (TM). We evaluate survival outcome of TM patients who do not require additional axillary treatment after identification of a +SLNB.
  • Article
    Citation - Scopus: 37
    The Impact of Onco Type Dx® Recurrence Score of Paraffin-Embedded Core Biopsy Tissues in Predicting Response To Neoadjuvant Chemotherapy in Women With Breast Cancer
    (IOS Press, 2016) Soran, Atilla; Bhargava, Rohit; Johnson, Ronald; Ahrendt, Gretchen; Bonaventura, Marguerite; Diego, Emilia; McAuliffe, Priscilla F.; Serrano, Merida; Menekşe, Ebru; Sezgin, Efe; McGuire, Kandace P.
    BACKGROUND: Oncotype DX® test is beneficial in predicting recurrence free survival in estrogen receptor positive (ER+) breast cancer. Ability of the assay to predict response to neoadjuvant chemotherapy (NCT) is less well-studied. OBJECTIVE: We hypothesize a positive association between the Oncotype DX® recurrence score (RS) and the percentage tumor response (%TR) after NCT. METHODS: Pre-therapy RS was measured on core biopsies from 60 patients with ER+, HER2.. invasive breast cancer (IBC) who then received NCT. Pre-therapy tumor size was measured using imaging. %TR, partial response (PR; 50%), pathologic complete response (PCR) and breast conserving surgery (BCS) rates were measured. RESULTS: Median RS was 20 (2 69). Median %TR was 42 (0 97)%. PR was observed in 43% of patients. There was no association between %TR and pre-NCT tumor size, age, Nottingham score or nodal status (p 0:05). No statistically significant association with %TR was seen with RS as a categorical or continuous variable (p = 0:21 and 0.7, respectively). Response to NCT improved as ER (p = 0:02) by RT-PCR decreased. Lower ER expression by IHC correlated with response (p = 0:03). CONCLUSIONS: In patients with ER+ IBC receiving NCT, RS did not predict response to NCT using %TR. The benefit of the assay prior to NCT requires further study.